Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Lidocaine Hydrochloride Gel from the National Medical Products Administration, marking a significant milestone in the company's product development and regulatory compliance [1][4]. Group 1: Drug Registration Certificate Details - The Drug Registration Certificate pertains to Lidocaine Hydrochloride Gel, which is indicated for local anesthesia during procedures requiring such intervention [1]. - The company is one of three domestic enterprises that have obtained this Drug Registration Certificate for the product [1]. - The estimated sales revenue for Lidocaine Hydrochloride Gel in national secondary hospitals and above is approximately 40.86 million yuan in 2024 [1]. Group 2: R&D Investment and Production Approval - As of the announcement date, the cumulative R&D investment for this project is approximately 7.27 million yuan (unaudited) [2]. - This is the first production license obtained by the company in 2026 [3]. Group 3: Impact on the Company - The acquisition of the Drug Registration Certificate for Lidocaine Hydrochloride Gel enhances the company's product line and is expected to improve its market competitiveness [4]. - The impact of this certificate on the company's near-term operating performance is not anticipated to be significant [4].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Lidocaine Hydrochloride Gel, which is expected to enhance its product line and competitiveness, although it is not anticipated to have a significant impact on recent performance [1] Group 1: Product Approval - The product is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation of generic drug quality and efficacy [1] - The registered specification of the drug is 2% (10g:0.2g) [1] Group 2: Financial Implications - Cumulative R&D investment in this project amounts to approximately 7.27 million yuan [1] - The estimated sales revenue for this product in secondary and higher-level hospitals across the country in 2024 is approximately 40.86 million yuan [1] Group 3: Strategic Impact - The approval of this product is expected to enrich the company's product line and enhance its competitive position in the market [1] - The company anticipates no major impact on its recent performance following this approval [1]

Core Viewpoint - The rapid growth of online healthcare in China has led to significant issues in the sale of prescription drugs on e-commerce platforms, posing serious risks to consumer safety due to lax regulations and practices [1][5]. Group 1: Prescription Drug Sales Issues - The process for purchasing prescription drugs online is alarmingly simple, with consumers not required to provide medical history or prescriptions, leading to "instant prescriptions" without proper medical evaluation [1][2][3]. - In a practical test, the time taken from consultation to prescription issuance was as short as 10 seconds, highlighting the lack of meaningful interaction between patients and online doctors [2][3]. - Some platforms allow for prescription issuance at any hour, with no restrictions on the timing of orders, further exacerbating the issue of oversight in prescription practices [5]. Group 2: Regulatory Violations - Online platforms are found to be in violation of regulations by displaying prescription drug packaging and information that should not be publicly accessible before prescription approval [6][8]. - Certain platforms promote prescription drugs for uses that exceed their approved indications, misleading consumers and potentially endangering their health [8][10]. - There are instances of products being marketed under names and packaging that closely resemble approved medications, raising concerns about counterfeit drugs and misleading advertising [10][12]. Group 3: Legal Implications - The sale of drugs with altered names and packaging may violate multiple laws, including those against unfair competition and drug management regulations, potentially leading to severe penalties for the sellers [12][13]. - Third-party platforms are urged to enhance their oversight of drug sales to prevent the distribution of unapproved or counterfeit medications, as failure to do so could result in shared liability for regulatory breaches [12].